LAB
Standard Biotools Inc
0.7399$
-0.4%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 50.3% | 49.0% | 70.4% | 67.7% | 66.6% | 61.4% | 59.4% | 90.9% | 87.5% | 80.0% | 81.6% | 82.4% | |
| 23.5% | 16.0% | 36.9% | 38.1% | 30.9% | 27.2% | 26.0% | 28.5% | 24.0% | 20.8% | 41.6% | 43.1% | |
| 38.0% | 35.6% | 59.4% | 55.7% | 53.8% | 47.8% | 44.5% | 42.6% | 36.1% | 33.0% | 71.2% | 76.0% | |
| 4.9% | 6.1% | 4.6% | 4.6% | 5.2% | 5.5% | 6.1% | 2.6% | 2.5% | 2.4% | 2.6% | 2.5% | |
| 6.5% | 6.4% | 5.2% | 6.0% | 6.3% | 6.7% | 7.3% | 4.3% | 4.7% | 3.5% | 2.9% | 2.7% | |
| 16.4% | – | – | – | 10.6% | 11.7% | 12.3% | 8.5% | 8.2% | 8.1% | – | – | |
| 31.3% | 32.9% | 13.7% | 15.0% | 15.6% | 18.2% | 19.3% | – | – | – | – | – | |
| 1.3% | 0.4% | 3.2% | 3.4% | 3.4% | 4.7% | 4.8% | – | – | – | – | – | |
| 138.8% | 49.5% | 25.8% | 28.0% | 28.2% | 23.0% | 21.6% | 23.8% | 25.9% | 25.3% | 12.2% | 13.9% | |
| 15.3% | 33.8% | 15.6% | 17.5% | 17.7% | 10.8% | 9.7% | 17.6% | 20.0% | 19.1% | 6.6% | 9.1% | |
| 2.6% | 19.8% | 7.8% | 8.6% | 9.0% | 1.0% | 1.1% | 0.9% | 0.9% | 1.0% | 0.9% | 0.9% | |
| 2.2% | 2.9% | 1.7% | 1.8% | 1.6% | 2.0% | 2.0% | 1.3% | 1.2% | 1.0% | 1.3% | 1.5% | |
| 17.6% | 1.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.1% | 0.1% | 0.1% | 0.0% | 0.0% | |
| -38.8% | 50.5% | 74.2% | 72.0% | 71.8% | 77.0% | 78.4% | 76.2% | 74.1% | 74.7% | 87.8% | 86.1% | |
| -289.1% | -309.8% | -138.7% | -158.7% | -169.0% | -193.6% | -209.1% | -223.6% | -237.2% | -222.0% | -177.4% | -185.0% | |
| 23.3% | 24.7% | 37.8% | 52.5% | 54.5% | 61.2% | 65.3% | 68.3% | 70.9% | 67.8% | 60.7% | 62.3% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.